Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
transdermal patch
|
| gptkbp:activeDuring |
buprenorphine
|
| gptkbp:availability |
generic version available
|
| gptkbp:clinicalTrials |
long-term safety
comparison with other opioids comparison with placebo pain management efficacy |
| gptkbp:contraindication |
acute or severe asthma
hypersensitivity to buprenorphine severe respiratory depression |
| gptkbp:date |
2010-11-30
|
| gptkbp:dosageForm |
patch
|
| gptkbp:drugInterdiction |
prescription only
opioid analgesic partial agonist steady-state achieved in 24 hours |
| gptkbp:formulation |
buprenorphine transdermal system
|
| gptkbp:healthcare |
avoid alcohol
dispose of properly do not cut patches |
| https://www.w3.org/2000/01/rdf-schema#label |
Butrans
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
CYP3A4 inducers other CNS depressants |
| gptkbp:label |
risk of addiction
black box warning risk of neonatal withdrawal syndrome risk of overdose risk of withdrawal symptoms |
| gptkbp:mandates |
moderate to severe pain
|
| gptkbp:manufacturer |
gptkb:Purdue_Pharma
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:numberOfStudents |
about 37 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:packaging |
single-use patches
|
| gptkbp:route |
transdermal
|
| gptkbp:sideEffect |
dizziness
headache nausea constipation somnolence |
| gptkbp:skills |
10 mcg/hour
20 mcg/hour 5 mcg/hour |
| gptkbp:storage |
room temperature
|
| gptkbp:usedFor |
chronic pain management
|
| gptkbp:uses |
once weekly application
|